Lutikizumab (ABT-981) 是一种抗 IL-1α 和 IL-1β 双变量结构域免疫球蛋白。Lutikizumab 结合并抑制 IL-1α 和 IL-1β。Lutikizumab 可用于骨关节炎的研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-IL-1a & IL1b Reference Antibody (Lutikizumab) is 196.56 kDa.

Anti-IL-1a & IL1b Reference Antibody (Lutikizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-IL-1a & IL1b Reference Antibody (Lutikizumab) is 100.00%, determined by SEC-HPLC.

Lutikizumab bound to IL-1α protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Lutikizumab bound in hu-IL-1α-His, and the EC50 was 0.050 nM.

Lutikizumab bound to IL-1β protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Lutikizumab bound in hu-IL-1β-His, and the EC50 was 0.037 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.